-
公开(公告)号：US10357562B2
公开(公告)日：2019-07-23
申请号：US14802247
申请日：2015-07-17
发明人： Robert Francis Garry , Luis Manuel Branco , Bruce Alan Bunnell , Russell B. Wilson , Samuel E. Hopkins
IPC分类号： A61K39/42 , A61K35/28 , C12N5/0775 , C07K16/10 , G01N33/68
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
-
公开(公告)号：US10537634B2
公开(公告)日：2020-01-21
申请号：US16176743
申请日：2018-10-31
IPC分类号： A61K39/395 , C07K17/02 , C07K16/10 , A61K39/12 , C07K14/005 , A61K39/00
摘要： Immunogenic influenza hemagglutinin-derived peptide compositions described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide compositions comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein bound to an immunogenic carrier protein, such as an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide compositions described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
-
公开(公告)号：US09649375B2
公开(公告)日：2017-05-16
申请号：US13828988
申请日：2013-03-14
IPC分类号： A61K39/395 , A61K39/12 , A61K39/00 , C07K14/005 , C07K16/10 , C07K17/02
CPC分类号： A61K39/3955 , A61K39/12 , A61K2039/6081 , C07K14/005 , C07K16/1018 , C07K17/02 , C07K2317/33 , C12N2760/16122 , C12N2760/16134
摘要： Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
-
公开(公告)号：US20190282694A1
公开(公告)日：2019-09-19
申请号：US16426911
申请日：2019-05-30
发明人： Robert Francis Garry , Luis Manuel Branco , Bruce Alan Bunnell , Russell B. Wilson , Samuel E. Hopkins
IPC分类号： A61K39/42 , C12N5/0775 , C07K16/10 , A61K35/28 , G01N33/68
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
-
公开(公告)号：US09101597B2
公开(公告)日：2015-08-11
申请号：US13826285
申请日：2013-03-14
发明人： Robert Francis Garry , Luis Manuel Branco , Bruce Alan Bunnell , Russell B. Wilson , Samuel E. Hopkins
CPC分类号： A61K39/42 , A61K35/28 , C07K16/10 , C07K2317/76 , C12N5/0667 , C12N2510/00 , G01N33/6854 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/421 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/469 , Y02A50/471 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481 , Y02A50/491
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
摘要翻译： 本文描述了附加表达特异性靶向病原体（例如病毒，细菌或寄生虫）或毒素的感染物种的多种免疫反应性多肽的免疫保护性原代间充质干细胞（IP-MSC）。 IP-MSC表达两种或更多种（例如，2至约100）免疫反应性多肽（例如，全抗体，单链抗体（ScFV），Fab或F（ab）2抗体片段，双抗体，抗体等） ，和任选的一种或多种其它免疫调节多肽，例如细胞因子如白细胞介素（例如IL-2，IL-4，IL-6，IL-7，IL-9和IL-12），干扰素 例如IFNα，IFN和bgr，或IFNω）等，其可增强免疫反应性多肽的有效性。
-
公开(公告)号：US11123427B2
公开(公告)日：2021-09-21
申请号：US16426911
申请日：2019-05-30
发明人： Robert Francis Garry , Luis Manuel Branco , Bruce Alan Bunnell , Russell B. Wilson , Samuel E. Hopkins
IPC分类号： A61K39/42 , A61K35/28 , C12N5/0775 , C07K16/10 , G01N33/68
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
-
公开(公告)号：US10137194B2
公开(公告)日：2018-11-27
申请号：US15591386
申请日：2017-05-10
IPC分类号： A61K39/395 , A61K39/12 , C07K14/005 , C07K16/10 , C07K17/02 , A61K39/00
摘要： Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
